The use of selective serotonin reuptake inhibitors in young children with pervasive developmental disorders: some clinical observations.
OBJECTIVE
To study the effects of a new group of psychotropic medications, the selective serotonin reuptake inhibitors (SSRIs), on some symptoms of young children (under 7 years old) with pervasive developmental disorders (PDD).


METHODS
Open clinical trial.


RESULTS
Medications produced positive results in half the children, particularly those with obsessional, repetitive, and anxiety symptoms. The medication was discontinued in half the children: one-quarter for worsening of symptoms and the other quarter for doubtful side effects.


CONCLUSIONS
SSRIs may have a role to play in ameliorating some symptoms of PDD. Further studies with standardized measurements, however, are needed to elucidate which children and what symptoms could benefit from which medication.
Awad
G A
GA
Department of Psychiatry, Hospital for Sick Children, Toronto, ON.
D002648:Child; D002675:Child, Preschool; D002658:Developmental Disabilities / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D017367:Selective Serotonin Reuptake Inhibitors